• 2020년 1월 7일 오전, 한국메나리니는 서울 중구에 위치한 롯데호텔에서 "BENEFIT 연구 결과 발표 기자간담회"를 열어, 베타차단제 '네비보롤'의 효과를 입증하는 "BENEFIT 연구"를 발표하였습니다.자세한 내용은 아래 기사를 참고해주세요. 감사합니다. No.매체명Headline 1보건뉴스네비보롤“고혈압환자혈압제어개선에효과적” 2메디소비자뉴스한국메나리니"네비보롤,고혈압한국인의혈압조절에효과" 3뉴스핌한국메나리니"고혈압치료제 '네비보롤',한국인에게효과입증" 4연합뉴스메나리니"고혈압치료제 '네비보롤'한국서도효과확인" 5아시아타임즈한국메나리니,고혈압약 '네비보롤'효과입증 6메디파나뉴스고혈압병용요법최적파트너‥`네비보롤`근거나왔다 7데일리메디"고혈압치료제 '네비보롤',한국인효과확인" 8한국경제메나리니"고혈압치료제 '네비보롤'한국서도효과확인" 9아주경제한국메나리니,고혈압약‘네비보롤’한국인에게도효과있어 10매일경제메나리니,고혈압치료제성분 `네비보롤`한국인대상으로효과확인 11메디칼업저버베타차단제네비보롤한국인고혈압치료효과입증 12전자신문한국메나리니,국내고혈압환자 '네비보롤'효과입증..."처방증가기대" 13데일리안한국메나리니“고혈압치료제네비보롤,한국서도혈압조절효과입증” 14헬스조선메나리니"베타차단제,맥박빠른젊은고혈압에유용" 15프라임경제한국메나리니"네비보롤,고혈압환자유효성·안전성입증" 16조선비즈"韓고혈압환자처방후효과있었다"…고혈압치료제네비보롤안전성확인 17EBN고혈압치료제 '네비보롤'한국서도유효성입증 18현대경제신문한국메나리니"고혈압약 '네비보롤',안전성·효능높아" 19메디칼트리뷴고혈압치료제 '구관이명관?'베타차단제한국인효과확인 20메디칼타임즈근거논란베타차단제 'BENEFIT연구'로새도약예고 21토요경제메나리니,고혈압치료제‘네비보롤’한국인대상효과입증 22보건타임즈한국메나리니‘네비보롤’亞고혈압환자의효과적인혈압조절입증 23헬스미디어&플랜한국메나리니 "고혈압치료제네비보롤효과입증" 24현대건강신문메나리니‘네비보롤’한국인고혈압환자,효과적혈압조절입증 25메디컬헤럴드'BENEFI연구결과발표'한국메나리니 '네비보롤사용한최대규모실제관찰연구'진행…"아시아고혈압환자효과적혈압조절입증" 26메디컬월드뉴스한국메나리니,네비보롤사용최대규모실제관찰연구결과발표 27시선뉴스고혈압치료제성분 '네비보롤'한국고혈압환자에게도효과확인...연구결 과발표 28중앙일보3세대베타차단제‘네비보롤’한국인혈압강하효과입증 29이엠디한국메나리니, BENEFIT연구결과발표기자간담회 30아크로팬한국메나리니 BENEFIT연구결과,네비보롤을이용한아시아고혈압환자의효과적인혈압조절입증 31시사저널메나리니“고혈압치료제‘네비보롤’한국인에게도효과” 32에너지경제메나리니,고혈압치료제성분‘네비보롤’국내환자대상으로효과입증 33의약품유통신문메나리니,고혈압치료제 '네비레트'한국인에게도유효
  • 손‧발톱 무좀 치료제 ‘풀케어’(시클로피록스)로 국내에도 잘 알려진 이탈리아 메나리니 그룹이 한국을 포함한 전 세계 68개국에서 3개 항생제들의 발매를 독점적으로 진행할 수 있는 권한을 확보했다.기사 원문 보기 ☞ http://www.yakup.com/news/index.html?mode=view&nid=223037&cat=16&cat2=&kind=news
  • The 17,000th employee of the Menarini Group is Lara, 28 years old, a young graduate in Chemistry and Pharmaceutical Technology from the University of Florence, who is now employed at Menarini Ricerche. Menarini is present in 136 countries world-wide and continues to invest heavily in Italy: out of17,000 Group employees, more than 3,700 work in Italy, almost 300 of whom hired over the lasttwo years and work in the Group’s Florentine headquarters. With an average age of 29, more than 90% of Menarini employees hold a degree or a technicaldiploma and cover highly qualified profiles. "We are proud of this achievement - said Lucia Aleotti and Alberto Giovanni Aleotti, Chairman and Vice Chairman of the Menarini Group - and take this opportunity to highlight how being able to hire the 17,000th staff member is largely due to the extraordinary work carried out by all our employees who, with enthusiasm and determination, are the true makers of the success of the Menarini Group." With the opening of two new affiliates in Peru and Colombia, investments in the Berlin and Pisaresearch centers, and the growth of Asia Pacific, Menarini's strategy has always been focused onboth the quality of their products and internationalization. Menarini closed the year 2017 with a urnover of 3.6 billion Euro. About the Menarini Group The Menarini Group is an Italian pharmaceutical company, 12th in Europe out of 5,255 companies, and 36th company in the world out of 20,862 companies, with a turnover of more than 3,5 billion Euro and more than 16,700 employees. The Menarini Group has always pursued two strategic objectives: Research and Internationalisation and is present in the most important therapeutic areas including products for cardiology, gastroenterology, pneumology/antibiotics, diabetology, anti-inflammatory agents/analgesics. With 16 production sites and 6 Research and Development centers, the Menarini Group has a strong presence throughout Europe and Asia, Africa, Central and South America. Menarini’s products are available in 136 countries worldwide. For further information please visit www.menarini.com